Synergistic anti-tumor immune response to combination immunotherapy consisting of anti-tumor antibodies, extended half-life Interleukin-2, and other immunomodulatory agents
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Chemical Engineering, 2016.
Main Author: | Zhu, Eric F. (Eric Franklin) |
---|---|
Other Authors: | K. Dane Wittrup. |
Format: | Thesis |
Language: | eng |
Published: |
Massachusetts Institute of Technology
2017
|
Subjects: | |
Online Access: | http://hdl.handle.net/1721.1/107872 |
Similar Items
-
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
by: Surana, Rishi, et al.
Published: (2016) -
Contribution of immune cells in synergistic anti-tumor effect of ablation and immunotherapy
by: Ningning He, et al.
Published: (2024-02-01) -
A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
by: Gerhard Frey, et al.
Published: (2024-12-01) -
Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy
by: Yu-Hang Duan, et al.
Published: (2022-09-01) -
Role of tumor cell pyroptosis in anti-tumor immunotherapy
by: Lincheng Zhang, et al.
Published: (2024-06-01)